Sentence examples for risk to competition from inspiring English sources

"We are confident that upon further review the F.T.C. will conclude that this acquisition poses no risk to competition and should be approved," said Don Harrison, a senior corporate counsel for Google.

The FCC chairman, Tom Wheeler, said in a statement: "The proposed merger would have posed an unacceptable risk to competition and innovation, including to the ability of online video providers to reach and serve consumers".

One has to balance "the theoretical risk to competition" against Microsoft's argument that "you are getting more bang for your buck" by having it contribute goods and services worth $1 billion, Judge Motz said.

"After an extensive investigation, we concluded that the combination of AT&T's land-based internet and video business with DirecTV's satellite-based video business does not pose a significant risk to competition," said Assistant Attorney General Bill Baer of the DoJ's antitrust division.

Lothian Buses argued that the result would be an effective monopoly and a serious risk to competition.

On Friday, FCC Chairman Tom Wheeler said the merger posed "unacceptable risk to competition and innovation".

The former head of CADE, economist Gesner Oliveira, says the risks to competition are serious.

Thomas Vinje, a partner in the Brussels office of Morrison & Foerster who is a legal adviser to the alliance, said the risks to competition posed by Windows XP were much greater than those of previous versions of the operating system.

"For example, telecoms services are increasingly sold to consumers in the form of bundles, sometimes with broadcasting content; this can offer consumer benefits, but may also present risks to competition".

Given the smaller size of call-off orders, it may prove challenging to monitor the awarding of all call-off orders for legal violations, creating risks to competition and transparency.

But now, with an estimated $89 billion in brand-name drug sales in the United States at risk to generic competition over the next five years, according to IMS Health, some drug makers are selling generics to offset revenue declines — as well as wring some post-patent profits from the innovative drugs they developed.